EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT
|
|
- Corey Rose
- 6 years ago
- Views:
Transcription
1 EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy 1
2 OBJECTIVES Comprehensive analysis of he validation function. Description of the validation product Support of the validation product Design of the Validation Quality System Objectives of Validation Quality System Quality Attributes of Validation Quality System Parameters affecting attributes Control of variables affecting quality system performance Risk management Monitoring performance Continuous improvements Documentation in the Validation Master Plan. VALIDATION: PRODUCT and INFRASTRUCTURE WHAT IS YOUR APPROACH TO VALIDATION? HOW DO YOU MANAGE THE VALIDATION FUNCTION? RISK AND VARIATION 2
3 OUTLINE Introduction and definitions Defining the validation function Validation Master Plan(s) Process validations and qualifications Lifecycle approach to process validiation Other processes and qualified systems Department management Positives and negatives Interactive discussions PLEASE PARTICIPATE 3
4 SUMMARY Lifecycle approach should be applied to all process validation and qualifications at site QbD approach should be applied to management of the validation quality system (QSbD) Maximize uniformity in validation / qualification approach Minimize variation in validation / qualification performance Department management infrastructure development Risk basis Pre-work and post-work Document above in the Validation Mater Plan 4
5 Validation Policy VALIDATION DOCUMENTS Policy and corporate templates VALIDATION MASTER PLAN (VMP) COMPILATION OR INDIVIDUAL VMP VALIDATION PROJECT MASTER PLAN Validation Lifecycle Documents Stage 1 documents Process Design Stage 2 documents Process Qualification VALIDATION PLAN Validation Protocol(s) Engineering Studies Others Validation Results / Report Stage 3 documents Continued Process Verification PQ requirements Routine monitoring Associated validation and qualification Other associated documents 5
6 IMPORTANCE OF VALIDATION DOCUMENTS Validation documents always requested in regulatory audits especially VMP! Validation documentation is retained forever Documents reviewed long after people are gone Documents must stand alone FDA auditors often focus on documentation VMP and specific validation documents often requested ahead of audit Early documents (Initiation, Plan, Protocol) reviewed when project is in-progress or not completed. VMP IS KEY DOCUMENT 6
7 IMPORTANCE OF VALIDATION DOCUMENTS NEW PROCESS VALIDATION GUIDANCE FDA Process Validation Guidance has greatly expanded the scope of validation Lifecycle approach documents from development through commercialization. Traditional validation documents (protocol and results) relatively less important New expectations for traditional validation documents Validation organizations should lead sites in transition to lifecycle approach Multiple groups at site must now contribute to process validation lifecycle approach Lifecycle approach being applied to all validation and qualification (equipment, facilities, cleaning, etc.) 7
8 TERMINOLOGY: PROCESS VALIDATION Process Validation Process Qualification -- PPQ Qualification Equipment #1 Equipment #2 Equipment #3 UO #1 UO #2 UO #3 Qualification HVAC Utilities Facilities Computers Analytical methods validation Cleaning process validation Packaging process validation Process is validated 8
9 FDA PROCESS VALIDATION GUIDANCE (2011) Definition: Collection and evaluation of data, from the process design stage throughout commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality products. Process validation involves a series of activities over the lifecycle of the product and process. Three stages of activities: Stage 1 Process Design Development and scale-up activities Stage 2 Process Qualification Reproducible manufacturing Stage 3 Continued Process Verification Routine manufacturing STAGE 1 AND STAGE 3 EMPHASIS NEW PARADIGM 9
10 FDA PROCESS VALIDATION GUIDANCE DOCUMENTATION FOCUS Before commercial distribution to consumers, a manufacturer should have gained a high degree of assurance in the performance of the manufacturing process consistently produce Manufacturers should: Understand the sources of variation Detect the presence and degree of variation Understand the impact of variation on the process and product attributes Control the variation in a manner commensurate with risk to process and product. to justify commercial distribution of the product. use ongoing programs to collect and analyze product and process data state if control of the process. 10
11 FDA PROCESS VALIDATION GUIDANCE DOCUMENTATION FOCUS Good project management and good archiving to capture scientific knowledge. Enhance accessibility of information later in lifecycle. Integrated team approach: Process engineering, industrial pharmacy, analytical chemistry, microbiology, statistics, manufacturing, and quality assurance. Scientific studies throughout the product lifecycle planned, documented, and approved. Greater control over higher-risk attributes. Reevaluate risks throughout product/process lifecycle. Homogeneity with batch and consistency between batches are goals of process validation. 11
12 TYPES OF VALIDATION MASTER PLANS 1. Validation Master Plan site document 2. Validation Master Plan function document Process Validation Master Plan Cleaning Validation Master Plan Other 3. Validation Project Master Plan major project management document 4. Validation Plan Individual validation document (Validation Initiation / Plan) 12
13 RECOMMENDATION: SITE DICTIONARY Validation Qualification FAT SAT IQ OQ PQ PV PPQ VMP Validation Project Plan Validation Plan Others 13
14 VALIDATION MASTER PLAN SITE DOCUMENT Overview, approach, content, risk analysis Chapters Major commitments timelines Accomplishments Document management Revisions CRITICAL DOCUMENT DESCRIPTION OF VALIDATION QUALITY SYSTEM 14
15 VALIDATION MASTER PLAN SITE DOCUMENT OVERVIEW, CONTENT, APPROACH, RISK ANALYSIS Overview: Description of VMP content Approach: Lifecycle approach to all types of validation / qualification Stage 1. Design and development Stage 2. Demonstration Stage 3. Monitoring and maintenance Content: Chapter list and chapter content Risk analysis: Basis for all activities General procedures applicable to all validation. 15
16 LIFECYCLE APPROACH RAMIFICATIONS Integration of validation with technical support Product R&D Product technical support Equipment/facilities/utilities engineering Process engineering Analytical R&D Analytical QA/QC Computer systems Others Integration of validation with QA Annual Product Reviews Stability Others 16
17 1. Introduction 2. Facilities 3. Utilities 4. Equipment 5. Process 6. Analytical 7. Cleaning VALIDATION MASTER PLAN SITE DOCUMENT EXAMPLE CHAPTERS 8. Computer systems 9. Others 17
18 VALIDATION MASTER PLAN SITE DOCUMENT CHAPTER CONTENT Chapter description, approach, content, risk analysis Policies Procedures Commitments (projects, CAPA, others) Appendix Reference list List of all products and reference # List of all cleaning and reference # List of all equipment and reference # List of all HVAC and reference # List of all utilities and reference # Other 18
19 CHAPTER APPENDIX Product or other # Product or other name Primary validation reference # Supplement validation reference # Dates CRITICAL REFERENCE SECTION 19
20 VALIDATION MASTER PLAN SITE DOCUMENT MAJOR COMMITMENTS TIMELINES MAJOR PROJECT LIST Validation project # Project title Major dates Responsibility Benefits / Negatives Management tool Audit tool -- benefits Communication +/- Motivational tool 20
21 VALIDATION MASTER PLAN SITE DOCUMENT ACCOMPLISHMENTS List of completed process validations List of completed qualifications Improvement projects Validation Quality System changes Benefits / Negatives Accomplishments list management tool Audit tool -- benefits Credibility / communication +/- Motivational tool 21
22 VALIDATION MASTER PLAN SITE DOCUMENT ACCOMPLISHMENTS DATE # TITLE xxxx Process Validation Product X xxxxx Cleaning Validation Product X 22
23 VALIDATION MASTER PLAN SITE DOCUMENT DOCUMENT MANAGEMENT -- REVISIONS DATE TITLE REASON FOR REVISION Q 20120Update Completed validations, new equipment Q 2013 Update Completed validations, new equipment Q 2013 Update Completed validations Q 2013 Update Completed validations, new commitments Q 2013 Update Completed validations, 2014 goals Q 2014 Update Completed validations Q 2014 Update Completed validations, new equipment UPDATE FREQUENCY DEPENDS ON NEED AND WORKLOAD 23
24 VALIDATION MASTER PLAN FUNCTION DOCUMENT Overview, content, approach, risk analysis Policies Procedures Commitments (projects, CAPA, others) Document management Revisions Appendix Reference list 24
25 Strategy and approach VMP CHAPTER EXAMPLE CLEANING VALIDATION Comprehensive lifecycle approach, Science and technical basis, Risk analysis, Variation identification and control (consistent with site and corporate docs) Procedures List of approved procedures Supporting information with reference documentation Product cleaning matrix Equivalent equipment Equipment surface area calculations Residue calculations Technical reports Templates Validation commitments and timelines Planned validations Improvement projects and timelines Planned projects Validation references List of all completed cleaning validations, #, date 25
26 RESPONSIBILITIES OF THE VALIDATION FUNCTION If products fail specifications, does validation have responsibility? If re-cleaning is routinely needed, does validation have responsibility? If equipment fails, does validation have responsibility? If QA receives an FDA-483 observation, does validation have responsibility for validated items? Is validation primarily a documentation library? THE PV GUIDANCE HAS CHANGED THE SCOPE, CONTENT, AND RESPONSIBILITY OF VALIDATION 26
27 PROCESS VALIDATIONS AND QUALIFICATIONS Lifecycle approach stages Stage 1 -- Key components of QbD for product / process development Stage 2 -- FDA expectations including enhanced documentation Stage 3 Continued process verification. Stages summarized: Understand, demonstrate, monitor and maintain 27
28 OTHER PROCESSES Cleaning, analytical, packaging Equipment processes HVAC, water Qualified systems -- Equipment, facilities, utilities Quality systems. 28
29 DEPARTMENT MANAGEMENT Infrastructure supporting lifecycle approach to process validation Keys to effective process validation lifecycle Risk management Apply QbD and lifecycle approach to validation department management Minimize internal variation through uniform approach to all validation / qualification. 29
30 DEFINITIONS AND OBJECTIVES Quality by Design (QbD) Validated processes and equipment Process of validation -- Lifecycle approach to process validation Stage 1 Stage 2 Stage 3 QbD consistency with process validation FDA Quality Systems Validation Quality System QbD / Lifecycle approach to the validation quality system Risk management applications 30
31 QUALITY BY DESIGN (QbD) Development Focus Target product profile (TPP) and critical quality attributes (CQA) Drug substance and excipient properties Formulation design and development Manufacturing process design and development Identification of critical process parameters (CPP) and critical material attributes (CMA) Risk assessment and design space Scale up, identification of variables, and control strategy Red = Original QbD 31
32 VALIDATED PROCESSES AND EQUIPMENT Process Validation Process Qualification Process Performance Qualification (PPQ) Qualification Equipment #1 Equipment #2 Equipment #3 Unit Op #1 Unit Op #2 Unit Op #3 Qualification HVAC Utilities Facilities Computers Analytical methods validation Cleaning process validation Packaging process validation Process is validated 32
33 PROCESS OF VALIDATION LIFECYCLE APPROACH TO PROCESS VALIDATION Definition: Collection and evaluation of data, from the process design stage throughout commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality products. Process validation involves a series of activities over the lifecycle of the product and process. Three stages of activities: Stage 1 Process Design Development and scale-up activities QbD approach Stage 2 Process Qualification Demonstrate reproducible manufacturing through conformance lots Stage 3 Continued Process Verification Routine manufacturing and monitoring of performance. STAGE 1 AND STAGE 3 EMPHASIS NEW PARADIGM 33
34 VALIDATION HISTORY CGMP includes Validation Development -- VALIDATION Change control Lifecycle approach Continuum --- UNDERSTANDING VALIDATION MAINTENANCE 34
35 QbD and PROCESS VALIDATION QbD provides focus on design and development. Integration of manufacturing experience throughout lifecycle will results in product and process continuing improvements. QbD consistent with ICH Q8 and Q11. Lifecycle approach to process validation integrates QbD principles. Lifecycle: Design/development > Performance > Monitoring/maintenance Lifecycle approach being applied to other processes, equipment, utilities, quality systems, etc. 35
36 FDA QUALITY SYSTEMS FDA Definition: Formalized business practices that define management responsibilities for organizational structure processes, procedures, and resources needed to fulfill product/service requirements, customer satisfaction, and continual improvement. Management responsibilities Resources Manufacturing Evaluation 36
37 Management Responsibilities FDA QUALITY SYSTEMS MODEL 1. Provide leadership 2. Structure the organization 3. Build your quality system to meet requirements 4. Establish policies, objectives, and plans 5. Review the system Resources 1. General arrangements 2. Personnel development 3. Facilities and equipment 4. Control outsourced operations Manufacturing 1. Design, develop, and document product and processes 2. Examine inputs 3. Perform and monitor operations 4. Address non-conformities Evaluation activities 1. Analyze data for trends 2. Conduct internal audits 3. Quality risk management 4. Corrective action 5. Preventive action 6. Promote improvement 37
38 VALIDATION QUALITY SYSTEM Validation of processes, equipment, facilities, etc. is component of all quality and manufacturing systems being inspected. FDA Inspection Approach Quality System Materials System Production system Equipment and Facilities System Packaging and Labeling System Laboratory Controls System Canada Quality Systems Approach. Inter-relationship of Quality Assurance GMP Quality Control Validation is a quality system. Validation mentioned in all FDA inspection systems Can QbD/lifecycle principles be applied to the validation quality system? 38
39 DEFINE VALIDATION FUNCTION Process validation and qualification Supportive infrastructure Administration, personnel, etc. 39
40 Two components: VALIDATION QUALITY SYSTEM 1. Validated products, processes (manufacturing, cleaning, packaging, etc.), equipment, utilities, facilities, control systems, computer systems, analytical instruments the product of the validation system. 2. The process of accomplishing validation the infrastructure of the validation function. Protocol strategies, testing approaches, documentation packages, approval committee responsibilities, document library, improvement projects, etc. 40
41 QbD and VALIDATION QUALITY SYSTEM (QSbD) Manufacturing Target product profile Critical quality attributes Critical process parameters Variation and controls Risk assessment Monitoring attributes and process Improvement projects Validation QS System objective System attributes System parameters Variation and controls Risk assessment Monitoring metrics Improvement projects 41
42 RISK MANAGEMENT ICH Q9 discusses risk management. Risk analysis determines everything. High risk activities must receive most attention. Risk analysis required for devices. 42
43 QbD PROCESS VALIDATION QSbD VALIDATION QUALITYSYSTEM -- LIFECYCLE APPROACH PRODUCT and PROCESS Target profile Critical quality attributes product specifications Critical process parameters Variables and control Risk assessment Continuous improvement LIFECYCLE APPROACH Design/development, PQ, Monitoring Improvements (Stage 1 Stage 2 Stage 3) ************************************************************************************************************************************************************************************** VALIDATION QUALITY SYSTEM Objectives system and individual process steps Attributes Parameters Variables and control Risk assessment Improvement projects LIFECYCLE APPROACH Design/development, Demonstration, Monitoring Improvements 43
44 VALIDATION PRODUCT PRODUCT : All validated products, processes (cleaning, packaging, analytical, etc.), equipment, facilities, control systems, computers, etc., including documentation. Documentation affirming performance PRODUCT/PROCESS LIFECYCLE APPROACH 1. Design and development Process understanding 2. PQ Process demonstration 3. Continuous process verification Monitoring and maintenance 44
45 MANAGEMENT RESPONSIBILITY VALIDATION QUALITY SYSTEM LIFECYCLE APPROACH Quality System Design Is the quality system properly designed to conduct the validation business process? What about outsourced products, outsourced processes, outsourced validation/qualification? Quality System Performance Does the quality system perform as designed? Quality System Monitoring and Maintenance What is done to maintain quality system performance? RISK AND VARIATION 45
46 QUALITY SYSTEM QUESTIONS Procedures for all validation quality system activities -- Manufacturing processes, cleaning processes, analytical processes, equipment qualifications, other qualifications, computer systems, and other categories of validation/qualification? Model documents for above categories of activities regarding validation initiation, validation plans, protocols, results, and reports? Validation documents templates? Validation training for validation personnel Validation training for associated functions? R&D, Technical support, others Validation training for document writers? Adequate number of validation personnel? Expertise of validation personnel? Expertise of Validation Approval Committee (VAC)? VAC responsibilities consistent with expertise? Technical writers? Personnel development and training? Validation facilities? Facility security? Document library? Electronic systems? Electronic systems to monitor throughput, open documents, errors, etc.? Monitoring on validated processes? Feedback, e.g., incidence of recleaning? Monitoring on qualified EFU? Feedback? 46
47 QbD and VALIDATION QUALITY SYSTEM Objectives Validation business process performance excellence Validation quality system attributes Business process performance attributes Validation quality system parameters Business process performance Variation and control Business system procedures and training Risk management Highest risk activities prioritized Validation quality system improvement Improvements based on evaluation activities 47
48 VALIDATION QUALITY SYSTEM BUSINESS PROCESS PROJECT INITIATION, DESIGN, AND DEVELOPMENT BY SITE FUNCTION (STAGE 1) 1. Validation provides information on future needs in support of PQ 2. Validation receives / accesses recommended documents PROCESS QUALIFICATON (PQ STAGE 2) 3. Validation initiation Sources of requests 4. VAC approval 5. Protocol written 6. VAC approval 7. Test results and post-validation recommendations 8. VAC approval 9. Validation administrative closure 10. Document storage POST VALIDATION (STAGE 3) 11. Post-validation protocol initiation 12. VAC approval 13. Test results 14. VAC approval 15. Validation administrative closure 16. Document storage 17. Monitor validated process, EFU, etc. performance 18. Validation reviews Deviations, CAPA, etc. IMPROVEMENT PROJECTS 19. Initiate validation improvement project 20. Complete validation improvement project including implementation 21. Complete validation change project 48
49 VALIDATION QUALITY SYSTEM BY DESIGN LIFECYCLE APPROACH INITIATION, DESIGN, AND DEVELOPMENT 1. Objective 2. Attributes and parameters 3. Variation and control of variation 4. Risk analysis 5. Monitoring PROCESS QUALIFICATION 1. Objective 2. Attributes and parameters 3. Variation and control of variation 4. Risk analysis 5. Monitoring POST VALIDATION 1. Objective 2. Attributes and parameters 3. Variation and control of variation 4. Risk analysis 5. Monitoring IMPROVEMENT PROJECTS 1. Objectives 2. Performance and implementation, 49
50 Objectives QbD APPROACH TO VALIDATION QUALITY SYSTEM BUSINESS PROCESS What are the goals of each process step? Attributes What makes a process step successful? Parameters What factors significantly influence the success of the process step? Variation and control of variation What variation in performance is expected and how is it controlled? Risk management What are highest risk activities? Prioritization, evaluation, and review highest level for highest risk Evaluation Review performance of validation quality system and subsystems Review performance of validatd processes, EFU, etc. 50
51 VALIDATION QSbD INITIATION, DESIGN, AND DEVELOPMENT Manufacturing Process Validation 1. Objective: Support for Stage 2 PQ 2. Attributes and parameters: Formulation / process justification document CQA and CPP identification Risk analysis document Variation and control of variation document 3. Variation: Multiple project teams. Competence and experience 4. Risk: Aseptic processes highest risk. Secondary packaging lowest risk 5. Monitoring: Improvement Projects 1. Validation training for technical personnel 2. Documentation practices training 3. Document outlines and model documents ABOVE ANALYSIS FOR SPECIFIC VALIDATION / QUALIFICATION 51
52 PROCESS QUALIFICATION (PQ) Manufacturing Process Validation VALIDATION QSbD 1. Objective: PV documentation 2. Attributes and parameters: PV Initiation and validation plan, protocol, and results meeting standards Documents sections consistent with site procedure Documents consistent with FDA PV guidance Document quality acceptable Acceptable grammar and punctuation 3. Variation: Background, experience, and competence of authors Validation Approval Committee standards 4. Risk analysis: Testing and acceptance criteria proportionate to risk level 5. Post validation monitoring recommendations consistent practice Improvement Projects 1. Validation training for validation document authors 2. Validation protocol writing training for document authors 3. Document outlines standards and model documents 4. Validation Approval Committee standards and training ABOVE ANALYSIS FOR SPECIFIC VALIDATION / QUALIFICATION 52
53 VALIDATION QUALITY SYSTEM -- PROBLEM EXAMPLES MANUFACTURING EQUIPMENT AND PROCESSES Operators did not perceive changes to be changes inadequate change control Everything was like-for-like or not significant. CLEANING VALIDATION No technical basis for cleaning Operators did whatever needed to get the job done. CLEANING VALIDATION SAMPLING Sampling personnel not adequately trained false negative data DOCUMENTATION Numerous documentation problems such as data recording, original data, back dating, etc. DOCUMENTATION COMPLIANCE Documentation not compliant with corporate requirements or regulatory expectations DOCUMENTATION GRAMMATICAL Documentation poorly written SAMPLING PROBLEMS Sampling personnel not adequately trained NON-STERILE CLEAN PROCESSES Sampling personnel not adequately trained in mmicrobiology LIKE-FOR-LIKE CHANGES No testing of correct installation 53
54 Validation Training Module VALIDATION QUALITY SYSTEM CORRECTIVE ACTION PROJECTS Validation Protocol Writer Training Cleaning Validation Training Cleaning Visual Inspection Training Documentation Practices Training Validation Approval Committee Training Validation Approval Committee Procedure and Responsibilities Validation Model Documents Like-for-Like Approval (non-protocol) Process Microbiology Training Validation Policy Changes RECORD CORRECTIVE ACTION PROJECTS IN VMP 54
55 WHY THE PROBLEM? -- VALIDATION CATEGORIES Process validations Manufacturing Cleaning Packaging Analytical Others Qualifications IQ, OQ, PQ; ASTM E2500 Equipment Facilities Utilities Computer systems Others EACH VALIDATION UNIQUE 55
56 R&D WHY THE PROBLEM? ORIGINATORS OF VALIDATION / QUALIFICATION PROJECTS Technical Support Process Engineering Facilities Engineering Maintenance Analytical R&D QA/QC Other EACH GROUP UNIQUE. EACH WITH SPECIFIC EXPERTISE. EACH WITH SPECIFIC LANGUAGE AND TERMINOLOGY. ALL ABOVE GROUPS MUST UNDERSTAND VALIDATION OBJECTIVES. 56
57 VALIDATION QUALITY SYSTEM LIFECYCLE QUANTITATIVE MONITORING -- EVALUATION Performance of validated products, processes, equipment, etc. Do validated processes, EFU, etc. have problems due to validation deficiency, amount of testing, risk evaluation? External audit observations Documentation quality Document throughput. Open validation projects time open Amendments to validation plan Amendments and deviations to protocols Rejected documents Validation failures Other document problems 57
58 OTHER APPLICATIONS QbD / Lifecycle approach to other quality systems Documentation in QSMP (equivalent to VMP) Examples: Material system Heparin Manual cleaning Methotrexate high risk Training Read and sign vs. OTJ. Level of training in OTJ. RISK AND VARIATION 58
59 POSITIVES AND NEGATIVES System performance orientation. Organized and comprehensive focus based on risk to the patient and the organization, strong message to employees and to auditors, credit in audits Cost effective -- High risk activities emphasized and prioritized Difficult to implement, internal audits, transparency, identify deficiencies, make commitments. 59
60 QbD / LIFECYCLE APPROACH POSITIVES Organized and comprehensive focus based on risk to the patient and the organization Based on successful concepts System design for each type of validation -- Gap analysis Risk analysis for each type of validation Cross-functional systems thinking Consistent prioritized mitigation activities across functions based on risk Variation identification and control strategy in Stage 1 Continuous improvements based on systems monitoring Standardized audit expectations and documentation Organization commitment, transparency, and credibility Track organization accomplishments completed Strong message to employees Strong message to auditors Potential credit in audits for projects completed and new commitments identified 60
61 QbD / LIFECYCLE APPROACH NEGATIVES Difficult Getting organized is extremely difficult Problem identification is difficult Risk analysis is difficult Gap analysis is difficult Changes are difficult Transparency Being open about gaps and deficiencies may have regulatory and political risks Organizational commitments Headcount needed to correct deficiencies Do the benefits outweigh the negatives? 61
62 IMPLEMENTATION 1. Identify high risk areas Example: Cleaning expertise Example: Aseptic processing 2. Senior management discussion risks to operation 3. Function management discussion risks to operation 4. Identify receptive individuals in high risk area 5. Training of appropriate individuals 6. Start slowly 7. Communication. Modify strategy as needed to insure success 8. Success is essential 9. Expand effort based on success 10. Expect resistance 62
63 SUMMARY 1 QbD (QSbD) / Lifecycle Approach to the Validation Quality System Concepts and Principles Quality by Design (QbD) Objectives Attributes Parameters Variation and control Risk management Lifecycle Approach to Process Validation Design and development Performance Monitoring and maintenance 63
64 SUMMARY 2 QbD (QSbD) / Lifecycle Approach to the Validation Quality System Validation Quality System function Product validated processes, equipment, utilities, computer systems, etc. Infrastructure Process of conducting validation Infrastructure lifecycle approach: 1. Design and develop -- Plan 2. Demonstrate performance Show everything works 3. Monitor Periodically check 4. Initiate improvement projects a indicated Fix problems 64
65 SUMMARY 3 QbD (QSbD) / Lifecycle Approach to the Validation Quality System Infrastructure Lifecycle approach and QbD Objectives -- Goals of each process step? Attributes Successful steps Parameters Factors influencing success Variation. Identify sources of variation Control of variation -- Training, etc. to minimize variation Risk -- management Prioritize highest risk activities Evaluation -- Review performance Note: Different validation have different problems. 65
66 SUMMARY 4 QbD (QSbD) / Lifecycle Approach to the Validation Quality System Review Performance Gap analysis: Problem areas Initiate corrective action Initiate training Example projects Write model documents Quantitative measurements: Throughput, failures, deviations, etc. These indicate problems with the validation QS. Positives and negatives Implementation difficult 66
67 INTERCTIVE DISCUSSION Managing validation is never discussed. Managing validation is difficult Implementing improvements is difficult Does the QSbD approach have merit? Please your comments, questions, suggestions, and criticisms. Thank you 67
68 PAUL L. PLUTA, PhD Editor-in-Chief Journal of Validation Technology Journal of GXP Compliance Associate Professor of Biopharmaceutics University of Illinois at Chicago (UIC) College of Pharmacy, Chicago, IL, USA Extensive pharmaceutical industry technical and management experience Contact: 68
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,
More informationThe long anticipated draft of the FDA s
This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based
More informationPMDA Perspective: Regulatory Updates on Process Validation Standard
CMC Strategy Forum Japan 2014 Tokyo, Japan, December 8-9, 2014 PMDA Perspective: Regulatory Updates on Validation Standard Kazunobu Oyama, PhD Office of Cellular and Tissue-based Products PMDA, Japan Disclaimer:
More information22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:
More informationMASTER PLANNING FOR VALIDATION
MASTER PLANNING FOR VALIDATION By: Gamal Amer, Ph.D. Principal, Premier Compliance Services, Inc. 1 Process Validation: General Principles and Practices Guidance to industry issued by the FDA in January
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationICH Quality Implementation Working Group POINTS TO CONSIDER
ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements
More informationOverview of Amgen s CQP Commissioning and Qualification Program Steve Wisniewski Principal Compliance Consultant, CAI Past Chairman ISPE C&Q COP
May 1-3, 2012 Javits Center New York, NY Introduction to ISPE GUIDE: SCIENCE AND RISK-BASED APPROACH FOR THE DELIVERY OF FACILITIES, SYSTEMS, AND EQUIPMENT & Overview of Amgen s CQP Commissioning and Qualification
More informationProcess Validation Guidelines. Report highlights 23 rd February 2018
Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability
More informationQuality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017
Quality Systems Indian Pharmaceutical Alliance Advanced GMP Workshops 2017 Presented by Patrick Costello on November 2017 Principal Scientific Administrator Manufacturing & Quality Compliance An agency
More informationQbD Concepts Applied to Qualification and Transfer of Analytical Methods
QbD Concepts Applied to Qualification and Transfer of Analytical Methods CMC Strategy Forum Latin America - 2014 Patrick Swann Senior Director Technical Development QbD = Quality by Design QbD - A systematic
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationPAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland
PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &
More informationEnabling Improvement through the Product Lifecycle: Change Management within a PQS
Enabling Improvement through the Product Lifecycle: Change Management within a PQS Denise DiGiulio, Senior Advisor OPQ Office of Process and Facilities PDA Chapter Meeting Melbourne, Australia April 3,
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationA COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION
A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION By Mark Mitchell, Principal Consultant, Process and Engineering, Pharmatech Associates, Inc. PHARMATECH WHITE PAPER.DOCX
More informationSeamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson
Seamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson Senior Management Consultant Agenda Introduction A state-of
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationTextvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf
Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern
More informationQbD and the New Process Validation Guidance
Page 1 of 6 Published on Pharmaceutical Processing (http://www.pharmpro.com) Home > QbD and the New Process Validation Guidance QbD and the New Process Validation Guidance Bikash Chatterjee and Wai Wong,
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationGuidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.
Guidance for Industry Process Validation: General Principles and Practices D M k T k Dr. Mark Tucker, F. Hoffman-La Roche, Ltd. Disclosures I am currently a Senior Technical Advisor at F. Hoffman -La Roche.
More informationWHO guidelines on quality risk management
Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating
More informationDATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS
GLOBAL PROVIDER, LOCAL SOLUTIONS IN YOUR LANGUAGE DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS Francesco Amorosi PhD Octorber 2017 DATA INTEGRITY & CSV:
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationQuality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationTHE NEW QUALITY PARADIGM OPPORTUNITIES AND EXPECTATIONS IN ICH Q8 Q9 Q10 Q11 DR. FRITZ ERNI
THE NEW QUALITY PARADIGM IN ICH Q8 Q9 Q10 Q11 OPPORTUNITIES AND EXPECTATIONS DR. FRITZ ERNI FRITZ@ERNI.NET THE NEW PARADIGM OR QUALITY BY DESIGN Why do we need it! Some background Information The impact
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationDeveloping a Robust Quality System to Assure Data Integrity
Developing a Robust Quality System to Assure Data Integrity Maryann Gribbin Chief Compliance Officer, Faith & Royale Consultants Co-Chair PDA Data Integrity Task Force Data Integrity Facts or information
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More informationProcess validation in medical devices
Process validation in medical devices Fulfil requirements with expert regulatory guidance 1TÜV SÜD Contents INTRODUCTION 4 VALIDATION PLANNING 5 INSTALLATION QUALIFICATION 7 OPERATIONAL QUALIFICATION 9
More informationChallenges in Implementing Knowledge Management within ICH Q10
Challenges in Implementing Knowledge Management within ICH Q10 SYMPOSIUM - New Frontiers in Manufacturing Technology, Regulatory - Brasilia Joseph C. Famulare Vice President, Global Head Compliance and
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationStrategies for Risk Based Validation of Laboratory Systems
Strategies for Risk Based Validation of Laboratory Systems Video Web Seminar September 23, 2004 Ludwig Huber E-mail: ludwig_huber@agilent.com Today s Agenda Background information: why risk assessment,
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 3rd PQRI/FDA Conference on Advancing
More informationRisk-Based Approach to Software Quality and Validation
Risk-Based Approach to Software Quality and Validation By Praxis Life Sciences 1925 West Field Court, Suite 125, Lake Forest, IL 60045 praxislifesciences.com +1(847) 295-7160 validationcenter.com Risk
More informationAnnex Draft Annex
Anmerkung 1: Dieses Vergleichsdokument wurde nach bestem Wissen und Gewissen erstellt und ist rechtlich nicht bindend. Es gelten die von der EMA veröffentlichten Dokumente in der jeweiligen Form. Anmerkung
More informationRegulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0)
Regulatory Overview Annex 11 and Part 11 Sion Wyn Conformity +[44] (0) 1492 642622 sion.wyn@conform-it.com 1 Two Key Regulations Annex 11 21 CFR Part 11 Apply to the regulated company, but often have a
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationRisk-based Approach to Part 11 and GxP Compliance
Welcome to our E-Seminar: Risk-based Approach to Part 11 and GxP Compliance 1 Intro Common Discussion Q: Do I really need to do this? Possible Answers A: Of course! (QA) B: Who cares, I have work to do!
More informationPrincipal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
More informationBasics Of Labwasher Cleaning Validation
Basics Of Labwasher Cleaning Validation A Q&A With James Espiritu, Laboratory Equipment Business Applications Manager, Miele Validation is vital to pharmaceutical processes because it assures quality,
More informationCurrent Features of USFDA and EMA Process Validation Guidance
Human Journals Review Article April 2016 Vol.:6, Issue:1 All rights are reserved by Patwekar S.L et al. Current Features of USFDA and EMA Process Validation Guidance Keywords: Pharmaceutical validation,
More informationLifecycle Management of Process Analytical Technology Procedures
Lifecycle Management of Process Analytical Technology Procedures IFPAC 2015 Marta Lichtig Senior Scientist in New Testing Technologies, ACS Member Contents General Comparison : PV guide to NIR model development
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationQbD In Drug Development. Mathew Cherian Ph.D. Director & Senior Fellow Pfizer, USA
QbD In Drug Development Mathew Cherian Ph.D. Director & Senior Fellow Pfizer, USA The Origin of QbD The concept of Quality by Design (QbD) was introduced by Romanian born US engineer Joseph Juran QbD was
More informationLifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
More informationEvolution of the CMC Review - ANDAs
Evolution of the CMC Review - ANDAs Susan Rosencrance, Ph.D. Director (Acting), Office of Lifecycle Drug Products Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research October 6,
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationEquipment Qualification Ensure Fit for Intended Use. IVT Amsterdam Conference Mary Sexton. 19 Mar 2015
Equipment Qualification Ensure Fit for Intended Use IVT Amsterdam Conference Mary Sexton 19 Mar 2015 Equipment Qualification Ensure Fit for Intended Use 1. Types of Qualification 2. Validating Equipment
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationPrevent Quality System Deficiencies by Conducting Effective Internal Audits. Whitepaper
Prevent Quality System Deficiencies by Conducting Effective Internal Audits Whitepaper An internal audit system is one of the most effective ways to monitor, analyze, control, and improve quality management
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationRisk-Based Approach to SAS Program Validation
Paper FC04 Risk-Based Approach to SAS Program Validation Keith C. Benze SEC Associates, Inc. 3900 Paramount Parkway, Suite 150 South Morrisville, NC 27560 ABSTRACT SAS is widely used throughout the FDA
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationProduct, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA
Product, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA Naheed Sayeed Manager, Technical Operations Process Validation, Apotex Inc. 1 Process Validation Life Cycle Stage
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationSolving Statistical Mysteries What Does the FDA Want?
3 7 25Temperature(degC) 40 3.4 6.6 2.6 3.6 75 Humidity % 1.6 5.3 50 No Base Present Yes Solving Statistical Mysteries What Does the FDA Want? Ronald D. Snee, PhD IVT Statistics in Validation Conference
More informationDemonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Wendy Zwolenski Lambert, CQM/OE, RAC CMC Strategy Forum January 28, 2013 aligns
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationIntroduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES
Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES William Garvey and Associates LLC 2016 Introduction About your instructor William (Bill) Garvey Important regulations and events Good Manufacturing
More informationEfficient Validation Strategies and VMPs
FDA Medical Device Industry Coalition Efficient Validation Strategies and VMPs Anne Holland Wilson Agenda History and Recent Trends Why Validate 21 CFR 820.75 Process Validation Standards and Guidance
More informationProcess Validation Guidelines. by Pramote Cholayudth Thai Industrial Pharmacist Association (TIPA)
Process Validation Guidelines by Pramote Cholayudth cpramote2000@yahoo.com Thai Industrial Pharmacist Association (TIPA) September 19, 2016 1 2 Process Validation References Hierarchy Law Regulatory Guidelines
More informationProposed New USP General Chapter: The Analytical Procedure Lifecycle 1220
Page 1 of 9 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Proposed New USP General Chapter: The Analytical Procedure
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationResponding to an FDA 483
Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest
More informationThe Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management
The Impact of Quality Culture on Quality Risk Management FDA Perspective on Quality Culture; how it Impacts Risk Management Teresa Gorecki Practice Lead Compliance Architects Agenda The WHAT Definitions
More informationTECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE
More informationReview Article Review on Quality by Designing for Metered Dose Inhaler Product Development Santosh R. Thorat * 1, Sarika M.
Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2015; 4(6): 324-330 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com
More informationQUALIFICATION and VALIDATION Open Discussion Workshop QP Forum 21 st April 2016
QUALIFICATION and VALIDATION Open Discussion Workshop QP Forum 21 st April 2016 Representatives from cross section of companies were at this workshop namely: Abbott, Stiefel, Abbvie, Pfizer, Helsinn, BMS,
More informationFDA Process Validation
Page 1 of 5 Published on Controlled Environments Magazine (http://www.cemag.us) Home > FDA Process Validation FDA Process Validation Wai Wong Working with the New 2011 Guidelines. In January 2011, the
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationUpdate on the Regulatory Considerations of Pharmaceutical Product Lifecycle Management (ICH Q12) from a Health Authority Perspective
Update on the Regulatory Considerations of Pharmaceutical Product Lifecycle Management (ICH Q12) from a Health Authority Perspective Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationQuality Management. Carlos Bachier, MD
Quality Management Carlos Bachier, MD Goals of Quality Management Ensure credibility of outcomes Improve patient safety and quality of processes Significantly reduce errors Quality Medical and Laboratory
More informationQbD (Quality by Design) Has industry benefited from this? WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting There are many facets to engineering for a healthier world. It is important to understand what surrounds us today and look into what we believe will surround us
More informationISO 9001:2015. Quality Manual Template.
www.iso-9001-checklist.co.uk Insert your company s name or logo, and address. This quality manual is the property of Your Company. It must not be reproduced in whole or in part or otherwise disclosed without
More informationRegulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products.
Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality March 22-24, 2017 TRACK #2 Achieving Drug Product Quality: Novel
More informationRobbie Morehead Project Manager
Profile The consultant is an accomplished quality professional with 27 years' extensive medical device, pharmaceutical, regulatory, and Food and Drug Administration (FDA) experience. The consultant s experience
More informationOsprey Technologies, LLC. Quality Manual ISO9001:2008 Rev -
February 8, 2015 1 Osprey Technologies, LLC Quality Manual ISO9001:2008 Rev - February 8, 2015 Released by Dave Crockett President 6100 S. Maple Avenue, Suite 117 Tempe, AZ 85283 www.osprey-tech.com February
More informationQuality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines
Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Longe Sunday Anthony Head- Quality Assurance May & Baker Nigeria Plc. Pharmacentre, Ota, Nigeria eaglesconsult@gmail.com; Slonge@may-
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE September/October 2008, Vol. 28 No. 5 This executive summary provides an overview of the second edition of the ISPE Baseline Guide:
More informationRegulation of Active Pharmaceutical Ingredients (API)
Regulation of Active Pharmaceutical Ingredients (API) Stephan Rönninger Head External Affairs Europe, International Quality June 21, 2013 SINDUSFARMA / ANVISA / FIP-IPS Conference, Brasilia Agenda Regulations
More informationImplementation Life-cycle SOP
1.0 Commercial in Confidence 11-Aug-2006 1 of 12 Implementation Life-cycle SOP Document No: H4_SOP_0100 Prepared by: David Brown Date: 11-Aug-2006 Version: 1.0 1.0 Commercial in Confidence 11-Aug-2006
More informationSupplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan
Supplier Oversight September 2014 PQRI Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Agenda Mylan Background Setting the Stage with a Scenario Current State Thinking Supplier Qualification
More informationHISTORY AND MILESTONES
HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing
More informationICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management
1 2 3 14 December 2017 EMA/CHMP/ICH/804273/2017 Committee for Medicinal Products for Human Use 4 5 6 7 ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle
More informationFDA Quality Metrics Guidance
FDA Quality Metrics Guidance Marlène García Swider, Ph.D., CQM, CSSBB Institute of Validation Technology Quality Metrics Conference February 22 24, 2016 Coronado Island, San Diego, CA Personal Claim This
More informationGMP In-house Training
Your benefits: Customised to fit your company s requirements - cost-effective and flexible! GMP In-house Training for the Pharmaceutical, API and Medical Device Industry We offer practice-oriented GMP
More informationMEASURE FOR MEASURE: QUALITY METRICS
MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust
More informationRegional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators
Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Focused on GMP in production of Active Pharmaceutical Ingredients and Oral Solid Dosage Forms Organized
More informationSAM National continuous monitoring coordinators (NCMC) regional meeting
SAM National continuous monitoring coordinators (NCMC) regional meeting Annex 19 SSP Rollout Page 1 Annex 19 Adopted by the Council on 25 February 2013; Became effective on 15 July 2013; and Became applicable
More informationInitiation of Validation
Initiation of Validation Design Review Who Validates? What Process to Validate? Process Validation Decision Tree When to Validate? Prospective Validation Concurrent Validation Retrospective Validation
More informationCSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017
CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection
More informationQuality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702
Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 11 Status : APPROVED Effective: 09/07/2017 Page 2 of 32 Quality Manual Table of Contents
More information